Tenesmus Clinical Trials

Find Tenesmus Clinical Trials Near You

Clinical Study Evaluating Safety and Efficacy of Pentoxifylline in Patients With Ulcerative Colitis

Status: Recruiting
Location: See location...
Intervention Type: Drug
Study Type: Interventional
Study Phase: Phase 2
SUMMARY

Ulcerative colitis (UC) is a persistent, idiopathic form of inflammatory bowel disease (IBD) marked by uninterrupted inflammation of the colon's mucosal lining, usually starting at the rectum and progressing proximally in a continuous manner. It manifests clinically with recurrent episodes of abdominal pain, bloody diarrhea, urgency, tenesmus, and weight loss. The precise cause of UC is still unknown; however, it is thought to arise from a multifactorial interaction involving genetic susceptibility, immune system dysregulation, disturbances in gut microbiota composition, and various environmental factors.

Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
Maximum Age: 70
Healthy Volunteers: f
View:

• Age ≥ 18 years

• Both male and female will be included

• Negative pregnancy test and effective contraception.

• Mild and moderate UC patients

Locations
Other Locations
Egypt
Fayoum University
RECRUITING
Al Fayyum
Time Frame
Start Date: 2026-01-20
Estimated Completion Date: 2027-02-20
Participants
Target number of participants: 60
Treatments
Active_comparator: Control group
Group 1 (Placebo Group): Participants in this arm were administered an inert placebo capsule twice per day, in combination with mesalamine at a total daily dose of 3 g, given as 1 g three times daily
Active_comparator: Pentoxifylline group
Group 2 (PTX Group): Individuals assigned to this group received PTX at a dose of 400 mg twice daily, together with mesalamine 1 g taken three times daily.
Sponsors
Leads: Ihab Elsayed Hassan

This content was sourced from clinicaltrials.gov